Tinnitus Guidelines and Their Evidence Base

Cortical tinnitus evaluation using functional near-infrared spectroscopy

Functional near-infrared spectroscopy (fNIRS) estimates the cortical hemodynamic response induced by sound stimuli. fNIRS can be used to understand the symptomatology of tinnitus and consequently provide effective ways of evaluating and treating the symptom.

OBJECTIVE

Compare the changes in the oxy-hemoglobin and deoxy-hemoglobin concentration of individuals with and without tinnitus using auditory stimulation by fNIRS.

METHODS

A tinnitus group (n = 23) and a control group (n = 23) were evaluated by an auditory task for assessing sound-evoked auditory cortex activity. The fNIRS was composed of 20 channels arranged into 4x2 arrays over the frontal, temporal and parietal cortices. Then, a passive listening block-paradigm design was adopted with reoccurring blocks of tasks with 15 s interspersed with randomized silence periods between 15-25 s.

RESULTS

There was a significant difference in the condition (type of sound), region of interest (ROI) and channel. As well as significant interaction in group and condition, and group and channel. The Tinnitus Frequency decreased HbO levels, while other sounds (white noise - WN and 1KHZ) increased HbO levels. All conditions differed from each other, except 1KHz with Baseline (silence) in the control group. Regarding the channels, the frontal channels (1, 3, and 11) differed in the tinnitus group, while in the control group a difference was observed in the channels of the frontal, temporal and parietal regions.

CONCLUSION

The type of sound presented, and brain region influenced the variations in HbO levels, but there was no difference between tinnitus and control participants. The tinnitus loudness, annoyance, and severity showed a weak correlation with variations in HbO levels.

Efficacy and safety of electroacupuncture and electroacupuncture combined with warm needling for subjective tinnitus: A multicenter, three-arm randomized controlled trial

OBJECTIVE

To evaluate the clinical efficacy and safety of electroacupuncture (EA) and electroacupuncture combined with warm needling (EAWN) on reducing tinnitus loudness and tinnitus-related distress among older adults.

METHODS

This multicenter, assessor-blinded, parallel-group, randomized clinical trial was conducted from December 2022 to April 2024 at three out-patient clinics in Hong Kong. Ninety eligible participants aged 50-70 years with subjective tinnitus for 0.5-24 months were equally randomized to EA, EAWN, or waitlist groups. Both treatment groups received two standardized treatment sessions per week for 5 weeks. The waitlist group received no treatment during the study period. The outcome measures were numeric rating scale (NRS) scores for tinnitus loudness, Tinnitus Handicap Inventory (THI) scores, and safety outcomes. Assessments were conducted at baseline, weeks 5 and 10.

RESULTS

Both EA and EAWN groups showed significantly greater reductions in NRS scores for tinnitus loudness than did the waitlist group at weeks 5 (mean difference [95 % confidence interval]; EA: -1.91 [-2.79 to -1.03]; P < 0.001; EAWN: -1.81 [-2.68 to -0.94]; P < 0.001) and 10 (EA: -2.03 [-2.95 to -1.11]; P < 0.001; EAWN: -1.98 [-2.92 to -1.04]; P < 0.001). Improvements in total THI scores were also greater in the intervention groups at weeks 5 (P < 0.01) and 10 (P < 0.001). The two intervention groups showed no significant differences. No serious adverse events were reported.

CONCLUSION

Both EA and EAWN therapies could be effective and safe treatments for subjective tinnitus in older adults.

Tinnitus risk factors and its evolution over time

Subjective tinnitus is an auditory percept unrelated to external sounds, for which the limited understanding of its risk factors complicates the prevention and management. In this study, we train two distinct machine learning models to predict tinnitus presence (how often individuals perceive tinnitus) and severity separately using socio-demographic, psychological, and health-related predictors with the UK Biobank dataset (192,993 participants, 41,042 with tinnitus). We show that hearing health was the primary risk factor of both presence and severity, while mood, neuroticism, and sleep predicted severity. The severity model accurately predicts tinnitus progression over nine years, with a large effect size for individuals developing severe tinnitus (Cohen's d = 1.3, ROC = 0.78). This result is validated on 463 individuals from the Tinnitus Research Initiative database. We simplify the severity model to a six-item clinical questionnaire that detects individuals at risk of severe tinnitus, for which early supportive care would be crucial.

Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting

BACKGROUND

Bimodal neuromodulation combining sound therapy with electrical tongue stimulation using the Lenire® device is emerging as an effective treatment for tinnitus.

METHODS

A single-arm retrospective chart review of 220 patients with tinnitus from the Alaska Hearing & Tinnitus Center examines the real-world outcomes of the recently FDA-approved Lenire treatment. To the best of our knowledge, this is the first assessment of Lenire from a real-world clinic in the United States. The primary endpoint examines the responder rate and mean change in Tinnitus Handicap Inventory (THI) after ~12 weeks of treatment in eligible patients with moderate or worse tinnitus. A responder represents a THI improvement of greater than seven points (i.e., minimal clinically important difference, MCID).

RESULTS

Here we show that, out of 212 patients with available data, there was a high responder rate of 91.5% (95% CI: 86.9%, 94.5%) with a mean improvement of 27.8 ± 1.3 (SEM) points, and no device-related serious adverse events. Furthermore, a THI MCID of seven points represents a consistent criterion for clinical benefit based on evidence from clinical practice settings.

CONCLUSIONS

These findings show that the Lenire device can be used to safely and effectively reduce tinnitus in a real-world clinical setting.

Efficacy of repetitive transcranial magnetic stimulation for subjective chronic tinnitus: a randomized controlled trial meta-analysis

Objectives

Chronic tinnitus affects approximately 10%-15% of the population. The long-term presence of severe tinnitus significantly impacts affected individuals' quality of life and emotional state. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive technique that employs pulsed magnetic fields to modulate neural activity. rTMS is considered a promising treatment strategy for chronic tinnitus. However, the therapeutic effect of rTMS on subjective chronic tinnitus remains inconclusive, and its validity is still a subject of debate among researchers.

Methods

To identify RCTs investigating rTMS for subjective chronic tinnitus, a comprehensive computerized search was conducted across multiple databases, including PubMed, The Cochrane Library, Embase, Web of Science, China Knowledge, WIPO, Wanfang, and the China Biomedical Literature Database (CBM). The search timeframe spanned from the inception of each database to 2 June 2024. Two independent investigators performed literature screening, data extraction, and quality assessment using the Cochrane Risk of Bias Assessment Tool. Meta-analysis was conducted using RevMan 5.4 software.

Results

Sixteen randomized controlled trials (RCTs) involving 1,105 chronic tinnitus patients were included. RTMS was superior to Sham rTMS in THI and VAS and had a positive effect on the short-term impact of THI (1 month), Still, this meta-analysis did not observe a positive effect of rTMS on the long-term implications of tinnitus (6 months). rTMS had no significant immediate effect on TQ and LM scores on tinnitus questionnaires.

Conclusion

This meta-analysis demonstrated that rTMS has some efficacy in chronic tinnitus. However, more RCTs are needed to validate its effectiveness, to support the effectiveness of repetitive transcranial magnetic stimulation for tinnitus with larger sample sizes and more follow-up data, and to explore the potential benefits of rTMS in chronic tinnitus.

Systematic review registration

https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024569403.

Efficacy of Nortriptyline-Topiramate and Verapamil-Paroxetine in Tinnitus Management: A Randomized Placebo-Controlled Trial

OBJECTIVE

To evaluate the efficacy of 2 drug combinations on tinnitus severity and associated stress, depression, sleep, and anxiety.

STUDY DESIGN

A randomized, double-blind, placebo-controlled clinical trial conducted between 2019 and 2023 for an 8-week duration.

SETTING

Single institution tertiary care center.

METHODS

The study recruited adult patients with moderate to severe tinnitus for 6 months or more. In total, 81 patients were assessed for eligibility, 78 were enrolled and randomized, and 67 were included in the per-protocol analysis. Patients were randomized into 3 groups (1:1:1). Group NT received nortriptyline-topiramate, group VP received verapamil-paroxetine, and group P received placebo.

RESULTS

A total of 19 patients in group NT, 22 in group VP, and 26 patients in group P were included in the per-protocol analysis. In group NT, the Tinnitus Functional Index (TFI) score decreased from 58.4 ± 13.9 (baseline) to 46.3 ± 17.5 (end-of-trial) (P < .001). Similarly, in group VP, the TFI score decreased from 54.6 ± 17.5 to 42.2 ± 16.1 (P = .004). However, group P did not demonstrate any significant decrease in the TFI score from 51.2 ± 18.6 to 45.2 ± 20.1 (P = .086). The between-arm analysis did not yield any statistical significance decrease in the TFI score (analysis of variance, P = .265).

CONCLUSION

Both combinations of drugs were promising in improving tinnitus severity. However, larger-scale trials with longer follow-up periods are warranted to validate our findings between groups.

Prediction of acoustic tinnitus suppression using resting-state EEG via explainable AI approach

Tinnitus is defined as the perception of sound without an external source. Its perceptual suppression or on/off states remain poorly understood. This study investigates neural traits linked to brief acoustic tinnitus suppression (BATS) using naive resting-state EEG (closed eyes) from 102 individuals. A set of EEG features (band power, entropy, aperiodic slope and offset of the EEG spectrum, and connectivity) and standard classifiers were applied achieving consistent high accuracy across data splits: 98% for sensor and 86% for source models. The Random Forest model outperformed other classifiers by excelling in robustness and reduction of overfitting. It identified several key EEG features, most prominently alpha and gamma frequency band power. Gamma power was stronger in the left auditory network, while alpha power dominated the right hemisphere. Aperiodic features were normalized in individuals with BATS. Additionally, hyperconnected auditory-limbic networks in BATS suggest sensory gating may aid suppression. These findings demonstrate robust classification of BATS status, revealing distinct neural traits between tinnitus subpopulations. Our work emphasizes the role of neural mechanisms in predicting and managing tinnitus suppression. Moreover, it advances the understanding of effective feature selection, model choice, and validation strategies for analyzing clinical neurophysiological data in general.

Ultrasound guided stellate ganglion block for the treatment of tinnitus

BackgroundTinnitus, a common auditory disorder, significantly impacts patient quality of life and lacks universally effective treatments. The integration of advanced imaging technology like ultrasound in therapeutic interventions offers new possibilities in healthcare.ObjectiveThis study evaluated the efficacy of ultrasound-guided stellate ganglion block as an innovative approach to managing tinnitus.MethodsEighty patients with tinnitus were randomly assigned to either a control group receiving standard drug therapy or an observation group treated with ultrasound-guided stellate ganglion block in addition to standard therapy. Key metrics, including clinical effectiveness rates, anxiety scores, and tinnitus disability index scores, were assessed pre- and post-treatment.ResultsPost-treatment outcomes revealed that the observation group exhibited significantly improved anxiety scores (38.74 ± 4.05 vs. 50.45 ± 4.86; P < 0.05) and tinnitus disability index scores (37.8 ± 17.56 vs. 50.4 ± 21.26; P < 0.05) compared to the control group. Additionally, the observation group achieved a 100% clinical efficacy rate, outperforming the control group's 84% (P < 0.05).ConclusionUltrasound-guided stellate ganglion block demonstrates superior efficacy in managing tinnitus compared to conventional drug therapy. This study underscores the potential of integrating advanced ultrasound technology into healthcare to optimize treatment outcomes for auditory disorders.

Continuous Improvement of Chronic Tinnitus Through a 9-Month Smartphone-Based Cognitive Behavioral Therapy: Randomized Controlled Trial

BACKGROUND

Tinnitus is the perception of sound without an external auditive stimulus and can be a severe burden for affected patients. Medical guidelines recommend cognitive behavioral therapy (CBT) for tinnitus treatment, which effectively improves tinnitus-related distress and anxiety.

OBJECTIVE

This study investigates the outcome of a 9-month smartphone-based CBT for patients with tinnitus.

METHODS

The randomized controlled clinical trial in this study investigates the efficacy of a smartphone-based CBT for 187 patients with chronic tinnitus over a 9-month treatment period. In the initial 3 months, a waiting list design was applied, and in the subsequent study phase, the data of both treatment groups were collectively analyzed. The scores on the Tinnitus Questionnaire (TQ); 9-item Patient Health Questionnaire (PHQ-9); 9-item Self-Efficacy, Optimism, Pessimism (SWOP-K9) questionnaire; and 20-item Perceived Stress Questionnaire (PSQ-20) were assessed as endpoints after 3 and 9 months of treatment.

RESULTS

We observed a statistically significant reduction in the tinnitus burden in patients who received the smartphone-based CBT intervention. Although no changes were observed initially in the TQ sum scores in the waiting control group (baseline mean, 37.8, SD 4.7; 3 months mean 37.5, SD 4.8; analysis of covariance [ANCOVA] P=.52), the scores significantly decreased once the app-based CBT had commenced. Data pooled from both groups revealed significant reduction in the TQ sum score by 12.49 (SD 1.44) (ANCOVA, P<.001) and 18.48 (SD 1.85) (ANCOVA, P<.001) points after 3 and 9 months, respectively, which was also clinically important. The calculated Cohen d was 1.38. Similarly, the scores on PSQ-20 (-9.14 points; ANCOVA, P<.001), PHQ-9 (-2.47 points; ANCOVA, P<.001), and SWOP-K9 (0.17 points; ANCOVA, P<.001) were significantly improved at the end of the therapy, with corresponding intermediate effect sizes after 9 months.

CONCLUSIONS

The data in our study provide evidence of statistically significant, clinically relevant, and continuous benefits of an app-based CBT intervention in patients with chronic tinnitus.

TRIAL REGISTRATION

Deutsches Register Klinischer Studien DRKS00022973; https://drks.de/search/de/trial/DRKS00022973.

Change in Tinnitus Severity After an Online Self-Paced Tinnitus Course: A Retrospective Cohort Study in Acute and Chronic Tinnitus Patients

Background: Tinnitus can significantly impact a patient's quality of life. As no evidence-based curative treatments exist, therapies such as cognitive behavioral therapy, tinnitus retraining therapy, acceptance and commitment therapy, and mindfulness-based interventions aim to minimize tinnitus severity and have been shown effective. Since traditional delivery can be costly and time-consuming and often has limited accessibility, therapies might also be provided via eHealth. This study investigates the change in tinnitus severity measured by the Tinnitus Functional Index (TFI) score after participation in an online self-paced tinnitus ("Still Tinnitus") course. The secondary aim was to identify predictors for the clinically relevant improvement after participation in this course. Methods: This retrospective record study included patients from Still Tinnitus course between March 2023 and July 2024. Patients were recruited via the Still Tinnitus website. Differences in the TFI scores from baseline and after completing the fifth (last) module of the course were calculated to investigate the change in tinnitus over time. Multivariate logistic analyses were performed to identify the possible predictors for the clinically relevant improvement after completion of the Still Tinnitus course. Results: In total, 122 patients were included in the study. The analysis revealed a clinically relevant reduction in the TFI score of 27.2 points. Multiple regression analyses showed that the "duration of the tinnitus" (OR 5.0; 95%CI: 1.537-16.240; p = 0.007) and "female sex" (OR 1.9; 95%CI 0.111-7.637; p = 0.030) are predictors for a clinically relevant improvement. Conclusions: In a convenience sample of tinnitus patients, the Still Tinnitus course may contribute to a clinically relevant reduction in tinnitus severity. A shorter duration of tinnitus and female sex were identified as significant predictors.

Short- and Long-Term Outcomes of e-Health and Internet-Based Psychological Interventions for Chronic Tinnitus: A Systematic Review and Meta-Analysis

Objective: e-Health or web-based systems in the field of tinnitus have gained increasing interest. Cognitive behavioral therapy (CBT) delivered via the internet is currently witnessing a surge in both attention and offerings. This systematic review analyzed the efficacy and sustainability of internet-based therapies aimed at reducing tinnitus distress and comorbidities such as anxiety, depression, and sleep disorders. The review exclusively considered randomized controlled trials (RCTs) in which trained personnel were actively involved during intervention. Methods: Utilizing search terms such as tinnitus, internet-based therapy, and e-Health therapy, we identified 155 studies, from which 37 RCTs were carefully examined for data availability. Primary outcome measures included treatment effects for tinnitus distress (Tinnitus Questionnaire and other questionnaires) and handicap (Tinnitus Handicap Inventory), while secondary outcomes encompassed depression, anxiety, and sleep problems. Meta-analyses were conducted employing random-effect models. A study effect model was applied, yielding a singular effect size for each sample. The effect sizes were examined for influences of various moderators. Results: We found a statistically significant large effect size for improvement in tinnitus distress (d = 0.83; [confidence interval 0.61-1.06] with total n = 450 for the experimental group and total n = 504 or the controls), while the reduction of tinnitus handicap was smaller (moderate effect size d = 0.59; [0.44-0.73]). Less strong but still significant effects resulted for depression, anxiety, and insomnia. Most of the long-term outcomes remained stable. As moderators, the risk of bias (RoB) and the severity of tinnitus manifestations were identified. Conclusions: Internet-based therapy provides a valuable avenue for initial therapeutic contact, as supporting component in tinnitus treatment if accompanied by therapists. The heterogeneous quality with high drop-out rates or partly high RoB and the wide range of interventions (counseling, eCBT, mindfulness) might be considered as a limiting factor for a first-line management in tinnitus. So far, the use of e-Health is dependent on availability or user preferences.

Analysis of clinical characteristics and predictive model for effective treatment of tinnitus in patients with transient compound sound therapy

Purpose

This study explored the clinical characteristics of patients with tinnitus who responded to sound therapy and established a predictive model to evaluate the effectiveness of this therapy according to the clinical characteristics.

Methods

A retrospective analysis was performed on 991 subjective tinnitus patients who received compound sound therapy in the Department of Otolaryngology of the local hospital from November 2019 to January 2022.

Results

We found that tinnitus patients with different therapeutic effects had significant differences in the tinnitus side (p = 0.007), tone loudness distortion feedback test (FBT) (p = 0.000), residual inhibition test (RIT) (p = 0.000), tinnitus frequency (p = 0.012) and sensation level (p = 0.023). The corresponding variables were screened by univariate logistic regression, and the selected variables were analyzed using multivariate logistic regression. The results showed that FBT (p = 0.003), RIT (p = 0.000) and tinnitus frequency (p = 0.029) were independent risk factors affecting the efficacy of compound sound therapy. A predictive model and nomogram for the efficacy of compound sound therapy for tinnitus were constructed based on independent risk factors. The area under the curve (AUC) of the model constructed in this study was 0.766 (95% CI = 0.725-0.807), indicating a certain prediction ability. The calibration curve revealed that the predicted results were in good agreement with the actual results.

Conclusion

The model can predict the prognosis of tinnitus in patients receiving compound sound therapy and help otolaryngologists make the best clinical decisions regarding tinnitus treatment.

Tinnitus and COVID-19: effect of infection, vaccination, and the pandemic

Introduction

The COVID-19 pandemic, which began worldwide around March 2020, has had an impact on hearing health, specifically tinnitus and hearing loss. Physiologically, COVID-19 infection, or medication used to treat the infection, has been reported to be a potential risk factor for tinnitus onset. In addition, tinnitus was reported to be a long COVID symptom or to occur after a COVID-19 vaccination in some cases. With most reports focused on the clinical population, this study aimed to investigate how the onset of tinnitus is associated with COVID-19 infection, long COVID, and COVID-19 vaccination in the general population based on self-report, while accounting for otologic and psychological symptoms.

Methods

In this study, a cross-sectional online survey that included general demographic questions, questions about tinnitus, hearing loss, hyperacusis, emotional status, and the Tinnitus Functional Index (TFI) was conducted.

Results

Completed survey data of 1,511 respondents who reported having tinnitus or believed to have COVID-associated tinnitus were included in the analysis. Participants were categorized into four groups based on their judgment regarding the etiology of their tinnitus: (1) COVID infection group, (2) long COVID group, (3) COVID vaccination group, and (4) pre-existing tinnitus group. The results suggest that tinnitus severity (estimated using TFI scores) was significantly lower in the pre-existing tinnitus group than in any of the COVID-associated tinnitus groups. While varying factors were found to contribute to tinnitus severity among the COVID-associated groups, overall, depression and/or anxiety accounted for the most variance in predicting tinnitus severity.

Discussion

The findings highlight the need to evaluate the impact of varying otologic and psychological symptoms in individuals with COVID-associated tinnitus for better patient-centered care.

The Out-of-pocket Expenses of People With Tinnitus in Europe

BACKGROUND

Despite the high frequency of tinnitus and its impact on wellbeing, little is known about its economic burden, and, to our knowledge, no data are available on out-of-pocket (OOP) expenses.

METHODS

In 2022, a survey was conducted on OOP costs of tinnitus. We enrolled 679 participants with slight, moderate, and severe tinnitus in Italy, United Kingdom, Netherlands, Germany, and Spain. We estimated annual OOP expenses for tinnitus-related healthcare visits, treatments, medications, and alternative medicine practices. Prevalence of tinnitus in the general population, obtained from a representative survey we conducted in Europe in 2017-2018, was used to generalize costs for people with any tinnitus at the national level.

RESULTS

OOP expenses were 368€ (95% confidence intervals [CI], 78€-690€), 728€ (95% CI, 316€-1,288€), and 1,492€ (95% CI, 760€-2,688€) for slight, moderate, and severe tinnitus, respectively, with annual expenditure of 565€ for people with any tinnitus: 209€ for healthcare visits; 93€ for treatments; 16€ for drugs; 64€ for hearing supporting systems; and 183€ for acupuncture, homeopathy, and osteopathy. Individuals with slight, moderate, and severe tinnitus expressed a willingness to invest 1.6, 4.3, and 7.0 times their monthly income, respectively, to achieve complete relief from tinnitus.

CONCLUSION

This study offers for the first time insights into the OOP expenses incurred by individuals with tinnitus. OOP expenses exhibited substantial variations based on severity status, accounting for more than 17 billion € in the countries considered. In terms of financial burden, these findings align tinnitus to the recognized leading disabilities, including back pain and migraine.

Effect of transcranial direct current stimulation on tinnitus modulation: A randomized, double-blind, and placebo-controlled clinical trial: Effect of tDCS on tinnitus modulation: A clinical trial

OBJECTIVES

To evaluate the short and long-term effects of anodal tDCS (a-tDCS) targeting the left temporoparietal area (LTA) on tinnitus severity, annoyance, and loudness.

METHODS

This is a double-blind, randomized, sham-controlled, and parallel-group clinical trial. A total of 42 individuals with tinnitus were randomized to a-tDCS (n = 24) or sham tDCS (n = 18). The a-tDCS group received tDCS over the LTA during five consecutive day sessions (2 mA, 20 min). The sham group received a placebo current with the same characteristics as the a-tDCS group. Participants were assessed at baseline, after the fifth session, and at the 30-day follow-up, using hearing assessments and symptom questionnaires.

RESULTS

There was no effect of comparison between groups or interaction effect (time x group) in all hearing assessments and symptom questionnaires. There was only a main effect of time for Tinnitus Handicap Inventory - THI [F(1.642, 45.988) = 5.128; p = 0.014; η2 = 0.155]. Bonferroni post hoc showed that there was a significant difference in THI in the sham group between pre and post-treatment [CI (0.107, 14.643; p = 0.046)]. However, there was no difference between pre-treatment and follow-up THI, or between post-treatment and follow-up THI. There was no treatment effect on tinnitus severity (assessed by Tinnitus Functional Inventory - TFI), tinnitus annoyance or loudness (assessed by Visual Analogue Scale - VAS), or tinnitus pitch, loudness or minimum masking level (assessed by tinnitometry).

CONCLUSION

Five consecutive sessions of a-tDCS targeting LTA do not improve tinnitus severity, annoyance, and loudness. Future studies should investigate if other tDCS protocols are effective or a combination of tDCS with other forms of treatment.

The Efficacy of a Food Supplement in the Treatment of Tinnitus with Comorbid Headache: A Statistical and Machine Learning Analysis with a Literature Review

INTRODUCTION

Tinnitus, the perception of sound without an external auditory stimulus, affects approximately 10-15% of the population and is often associated with significant comorbidities such as headaches. These conditions can severely impact the quality of life. The aim of this study was to evaluate the efficacy of a food supplement in reducing the symptoms of both tinnitus and headache in patients experiencing these conditions concurrently.

METHODS

This prospective study included 32 patients (21 males and 11 females) aged between 23 and 68 years (mean age 49.38 years) who were experiencing both tinnitus and headache. The study assessed the impact of a food supplement on tinnitus and headache over a 90-day treatment period using three main instruments: the Tinnitus Handicap Inventory (THI), the Headache Impact Test (HIT-6), and a Visual Analog Scale (VAS) for discomfort. Statistical analyses, including paired t tests, were conducted to compare pre- and posttreatment scores. In the same dataset, Ridge Regression, a linear regression model with L2 regularization, was used to predict posttreatment scores (THI90, HIT90, VAS90).

RESULTS

The results indicated a statistically significant reduction in all three measures after 90 days of treatment. The mean THI score decreased from 29.81 to 27.06 (p = 0.011), the mean HIT-6 score decreased from 50.41 to 48.75 (p = 0.019), and the mean VAS score for discomfort decreased from 7.63 to 7.13 (p = 0.033). The optimal Ridge Regression model was found with an "alpha" value of approximately 3.73. The performance metrics on the test set were as follows: Mean Squared Error (MSE) of 13.91 and an R-squared score of 0.61, indicating that the model explains approximately 61% of the variance in the posttreatment scores. These results indicate that pretreatment scores are significant predictors of posttreatment outcomes, and gender plays a notable role in predicting HIT and VAS scores posttreatment.

CONCLUSION

This study demonstrates that a food supplement is effective in reducing the symptoms of tinnitus and headache in patients suffering from both conditions. The significant improvements in THI, HIT-6, and VAS scores indicate a positive impact on patient quality of life. Further research with larger sample sizes and more detailed subgroup analyses is recommended to fully understand the differential impacts of treatment across various demographics.

The Current State of Tinnitus Diagnosis and Treatment: a Multidisciplinary Expert Perspective

Tinnitus, the perception of sound without an external source, affects 15% of the population, with 2.4% experiencing significant distress. In this review, we summarize the current state of knowledge about tinnitus management with a particular focus on the translation into clinical practice. In the first section, we analyze shortcomings, knowledge gaps, and challenges in the field of tinnitus research. Then, we highlight the relevance of the diagnostic process to account for tinnitus heterogeneity and to identify all relevant aspects of the tinnitus in an individual patient, such as etiological aspects, pathophysiological mechanisms, factors that contribute most to suffering, and comorbidities. In the next section, we review available treatment options, including counselling, cognitive-behavioral therapy (CBT), hearing aids and cochlear implants for patients with a relevant hearing loss, sound generators, novel auditory stimulation approaches, tinnitus retraining therapy (TRT), pharmacological treatment, neurofeedback, brain stimulation, bimodal stimulation, Internet- and app-based digital approaches, and alternative treatment approaches. The evidence for the effectiveness of the various treatment interventions varies considerably. We also discuss differences in current respective guideline recommendations and close with a discussion of how current pathophysiological knowledge, latest scientific evidence, and patient perspectives can be translated in patient-centered care.

Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial

Bimodal neuromodulation is emerging as a nonsurgical treatment for tinnitus. Bimodal treatment combining sound therapy with electrical tongue stimulation using the Lenire device is evaluated in a controlled pivotal trial (TENT-A3, NCT05227365) consisting of 6-weeks of sound-only stimulation (Stage 1) followed by 6-weeks of bimodal treatment (Stage 2) with 112 participants serving as their own control. The primary endpoint compares the responder rate observed in Stage 2 versus Stage 1, where a responder exceeds 7 points in the Tinnitus Handicap Inventory. In participants with moderate or more severe tinnitus, there is a clinically superior performance of bimodal treatment (58.6%; 95% CI: 43.5%, 73.6%; p = 0.022) compared to sound therapy alone (43.2%; 95% CI: 29.7%, 57.8%), which is not observed in the full cohort across all severity groups. Consistent results are observed for the secondary endpoint based on the Tinnitus Functional Index (bimodal treatment: 45.5%; 95% CI: 31.7%, 59.9%; sound-only stimulation: 29.6%; 95% CI: 18.2%, 44.2%; p = 0.010), where a responder exceeds 13 points. There are no device related serious adverse events. These positive outcomes led to FDA De Novo approval of the Lenire device for tinnitus treatment.

Tinnitus Stepped-Care: A Model for Standardizing Clinical Services for Tinnitus

Clinical services for tinnitus have expanded greatly since the "masking" method was introduced by Jack Vernon in the 1970s. According to PubMed, the number of peer-reviewed publications has increased dramatically since that time (seven with "tinnitus" in the title in 1975; 477 in 2023). With so much research and overall interest, it might be expected that tinnitus services have improved accordingly. In reality, there are many variations of treatment, but no one method has been shown to be more effective than any other. This diversity of methods is evident when researching "tinnitus" on the internet and considering the many different ways clinicians offer tinnitus services. Some offer an evidence-based method but may not have the competency to ensure fidelity. Further is the proliferation of commercial methods that can cost thousands of dollars. In this article, I propose a framework for providing tinnitus clinical services called Tinnitus Stepped-Care. This framework does not promote specific procedures for tinnitus assessment and treatment, but rather suggests guiding principles that are essential in each of six progressive steps of tinnitus clinical care. It is further proposed to test the stepped-care model in the (currently under development) Tinnitus Learning Health Network (TLHN). The TLHN would consist of a network of clinicians, patients, and researchers from around the world who collaborate in establishing "best tinnitus practices." Collaboration would involve using and sharing data for the ongoing monitoring of a large, diverse, well-described patient population, and using quality improvement science to test and monitor outcomes over time, to determine the most effective treatments for different subgroups of tinnitus patients.

Ginkgo biloba extract prescriptions are associated with less frequent repeat visits to ENT doctors due to tinnitus: a retrospective cohort study

Objectives

We aimed to evaluate the drug utilization of Ginkgo biloba extract (Gbe), systemic corticosteroids (CSs), and pentoxifylline (PTXF) for the treatment of acute tinnitus by analyzing electronic patient health record data. In addition, we assessed whether the different drug treatments were associated with different frequencies of repeat visits to ear, nose, and throat (ENT) doctors.

Methods

This retrospective cohort study used data from the IQVIA Disease Analyzer (DA) database. It included patients with an initial diagnosis of tinnitus between January 2005 and December 2021, treated by ENT specialists in Germany.

Results

Of 111,629 patients meeting all selection criteria, 51,205 received prescriptions of Gbe, 34,817 of systemic CSs, and 25,607 of PTXF. Gbe prescription was associated with significantly lower odds of a repeat consultation due to tinnitus compared to systemic CSs [odds ratio (OR) 0.91; 95% confidence interval (CI): 0.88-0.95] as well as PTXF (OR 0.74; 95% CI: 0.72-0.77). This association was significant in both men and women and in some age groups.

Conclusion

Gbe is the most frequently ENT specialist-prescribed drug for the treatment of acute tinnitus. It is associated with a reduced likelihood of patients consulting their ENT specialist for tinnitus again compared to systemic CSs and PTXF.

A scoping review of tinnitus research undertaken by New Zealand researchers: Aotearoa-an international hotspot for tinnitus innovation and collaboration

Tinnitus is a very common oto-neurological disorder of the perception of sound when no sound is present. To improve understanding of the scope, strengths and weaknesses of New Zealand tinnitus research, a critical scoping review was undertaken. The aim was to help develop priorities for future research. A review of the literature was undertaken using a 6-stage scoping review framework of Scopus and Pub Med were searched in May 2023 with the combination of following key word [Tinnitus] and country of affiliation [New Zealand]. The search of PubMed resulted in 198 articles and that of Scopus 337 articles. After initial consideration of title relevance to the study (165 from PubMed and 196 from Scopus) removal of duplicates and after reading the articles and adding from references, 208 studies were chosen for charting of data. Nine themes were identified and described: A. Epidemiology; B. Models; C. Studies in animals; D. Mechanisms; E. Assessment and prognosis; F. Pharmacotherapy; G. Neuromodulation; H. Sensory therapies; I. Clinical practice. An urgent priority for future tinnitus research in NZ must be to address the absence of cultural and ethnic diversity in participants and consideration of traditional knowledge.

Tinnitus prevalence and care experience among population of Almaty city

The prevalence of tinnitus is increasing worldwide along with the aging population. The absence of a gold standard for diagnosis and treatment makes it difficult to assess the health status of a patient with tinnitus.The aim was to determine the prevalence of tinnitus among older adults in Almaty city and to evaluate the healthcare experience among the respondents who received treatment for tinnitus.

Methods

A cross-sectional study was conducted among people aged 18 years and above in Almaty city. The data were collected using a questionnaire sent via a Google form and/or as a printed version. Fully completed responses were received from 851 respondents. The questionnaire consists of 31 questions. Simple and multiple logistic regression analyses were performed to identify the risk factors of tinnitus.

Results

The prevalence of tinnitus in Almaty was 23.3%. The data showed that smoking and sleep regimen were associated with tinnitus. Older respondents indicated more symptoms associated with tinnitus than younger respondents did. Additional consultation was needed as part of the treatment of tinnitus. In addition, 49.4% of the respondents indicated a need of a support group for people with tinnitus. The respondents also indicated that the access to appropriate resources for the treatment of tinnitus was poor.

Conclusion

Similar to other studies, this analysis confirmed that tinnitus is prevalent in the adult population of Almaty city. Future activities should include measures for the improvement of public awareness of the risk factors of tinnitus, and multidisciplinary teamwork among healthcare specialists should be improved.

Tinnitus: Clinical Insights in Its Pathophysiology-A Perspective

Tinnitus, the perception of sound without a corresponding external sound source, and tinnitus disorder, which is tinnitus with associated suffering, present a multifaceted clinical challenge due to its heterogeneity and its incompletely understood pathophysiology and especially due to the limited therapeutic options. In this narrative review, we give an overview on various clinical aspects of tinnitus including its heterogeneity, contributing factors, comorbidities and therapeutic pathways with a specific emphasis on the implications for its pathophysiology and future research directions. Tinnitus exhibits high perceptual variability between affected individuals (heterogeneity) and within affected individuals (temporal variability). Hearing loss emerges as predominant risk factor and the perceived pitch corresponds to areas of hearing loss, supporting the compensatory response theory. Whereas most people who have tinnitus can live a normal life, in 10-20% tinnitus interferes severely with quality of life. These patients suffer frequently from comorbidities such as anxiety, depression or insomnia, acting as both risk factors and consequences. Accordingly, neuroimaging studies demonstrate shared brain networks between tinnitus and stress-related disorders shedding light on the intricate interplay of mental health and tinnitus. The challenge lies in deciphering causative relationships and shared pathophysiological mechanisms. Stress, external sounds, time of day, head movements, distraction, and sleep quality can impact tinnitus perception. Understanding these factors provides insights into the interplay with autonomic, sensory, motor, and cognitive processes. Counselling and cognitive-behavioural therapy demonstrate efficacy in reducing suffering, supporting the involvement of stress and anxiety-related networks. Hearing improvement, especially through cochlear implants, reduces tinnitus and thus indirectly validates the compensatory nature of tinnitus. Brain stimulation techniques can modulate the suffering of tinnitus, presumably by alteration of stress-related brain networks. Continued research is crucial for unravelling the complexities of tinnitus. Progress in management hinges on decoding diverse manifestations, identifying treatment-responsive subtypes, and advancing targeted therapeutic approaches.

AUDISTIM® Day/Night Alleviates Tinnitus-Related Handicap in Patients with Chronic Tinnitus: A Double-Blind Randomized Placebo-Controlled Trial

The aim of this study is to evaluate the efficacy of taking a daily supplement based on active compounds (AUDISTIM® Day Night: A D/N) in alleviating tinnitus-related disability, as suggested by previous real-life studies. This double-blind randomized placebo-controlled study was conducted in adults with mild to severe tinnitus receiving a 3-month supplementation with A D/N (magnesium, vitamins, phytochemicals) or placebo (excipients without active ingredients). Tinnitus-related handicap (THI), psychological stress (MSP-9), and sleep quality (PSQI) were assessed at baseline and during intervention, perceived impression of tinnitus improvement at the end of the follow-up. The full set analysis included 114 patients (59 A D/N, 55 placebo) aged 53.8 ± 11.4 years, 58% women, with fluctuating (45%) or permanent (55%) tinnitus from 9.3 ± 9.4 years. A D/N supplementation led to greater changes in THI (-13.2 ± 16.0 vs. -6.2 ± 14.4, p = 0.0158,Cohen's d =0.44) at 3 months (primary outcome), especially with continuous tinnitus (-15.0 ± 16.3 vs. -4.6 ± 12.8, p = 0.0065), and, to a lesser extent, at 1 month (-9.8 ± 13.1 for A vs. -4.3 ± 12.1, p = 0.0213). PSQI significantly improved over time in both groups, but MSP-9 only with A D/N. In lines with previous observational studies, both clinical (THI score > 7 pts) and statistical (vs. placebo) improvement, more pronounced in permanent tinnitus, demonstrate the effectiveness of the combination of active compounds and support its use in the management of mild to severe tinnitus.

Functional MRI Neurofeedback Outperforms Cognitive Behavioral Therapy for Reducing Tinnitus Distress: A Prospective Randomized Clinical Trial

Background Cognitive behavioral therapy (CBT) is the current standard treatment for chronic severe tinnitus; however, preliminary evidence suggests that real-time functional MRI (fMRI) neurofeedback therapy may be more effective. Purpose To compare the efficacy of real-time fMRI neurofeedback against CBT for reducing chronic tinnitus distress. Materials and Methods In this prospective controlled trial, participants with chronic severe tinnitus were randomized from December 2017 to December 2021 to receive either CBT (CBT group) for 10 weekly group sessions or real-time fMRI neurofeedback (fMRI group) individually during 15 weekly sessions. Change in the Tinnitus Handicap Inventory (THI) score (range, 0-100) from baseline to 6 or 12 months was assessed. Secondary outcomes included four quality-of-life questionnaires (Beck Depression Inventory, Pittsburgh Sleep Quality Index, State-Trait Anxiety Inventory, and World Health Organization Disability Assessment Schedule). Questionnaire scores between treatment groups and between time points were assessed using repeated measures analysis of variance and the nonparametric Wilcoxon signed rank test. Results The fMRI group included 21 participants (mean age, 49 years ± 11.4 [SD]; 16 male participants) and the CBT group included 22 participants (mean age, 53.6 years ± 8.8; 16 male participants). The fMRI group showed a greater reduction in THI scores compared with the CBT group at both 6 months (mean score change, -28.21 points ± 18.66 vs -12.09 points ± 18.86; P = .005) and 12 months (mean score change, -30 points ± 25.44 vs -4 points ± 17.2; P = .01). Compared with baseline, the fMRI group showed improved sleep (mean score, 8.62 points ± 4.59 vs 7.25 points ± 3.61; P = .006) and trait anxiety (mean score, 44 points ± 11.5 vs 39.84 points ± 10.5; P = .02) at 1 month and improved depression (mean score, 13.71 points ± 9.27 vs 6.53 points ± 5.17; P = .01) and general functioning (mean score, 24.91 points ± 17.05 vs 13.06 points ± 10.1; P = .01) at 6 months. No difference in these metrics over time was observed for the CBT group (P value range, .14 to >.99). Conclusion Real-time fMRI neurofeedback therapy led to a greater reduction in tinnitus distress than the current standard treatment of CBT. ClinicalTrials.gov registration no.: NCT05737888; Swiss Ethics registration no.: BASEC2017-00813 © RSNA, 2024 Supplemental material is available for this article.

Should Tinnitus Patients with Subclinical Hearing Impairment Be Offered Hearing Aids? A Comparison of Tinnitus Mitigation Following 3 Months Hearing Aid Use in Individuals with and without Clinical Hearing Impairment

There is a consensus among tinnitus experts to not recommend hearing aids for tinnitus patients with subclinical hearing impairment. However, this notion is arbitrary, as no previous study has compared the treatment effect of hearing aids on tinnitus distress in patients with and without clinical hearing impairment. In this article, we investigate whether tinnitus patients with clinical and subclinical hearing impairment differ in terms of tinnitus mitigation after hearing aid fitting. Twenty-seven tinnitus patients with either clinical (n = 13) or subclinical (n = 14) hearing impairment were fitted with hearing aids. All participants filled out the tinnitus functional index (TFI) before hearing aid fitting and after 3 months of hearing aid use. Clinically meaningful reductions in tinnitus distress (-13 TFI points or more) were seen in both groups, and the difference in tinnitus mitigation between tinnitus patients with clinical (mean TFI reduction = 17.0 points) and subclinical hearing impairment (mean TFI reduction = 16.9 points) was not statistically significant (p = 0.991). Group differences on the suspected confounding factors of age, sex, time since tinnitus debut, tinnitus distress (TFI score) at baseline, and treatment adherence were statistically insignificant. In light of this, we argue that clinical hearing impairment is not required to achieve meaningful tinnitus mitigation with hearing aids, and that hearing aids could be recommended for tinnitus patients with subclinical hearing impairment.

Analysis and comparison of clinical practice guidelines regarding treatment recommendations for chronic tinnitus in adults: a systematic review

OBJECTIVES

To determine if, and to what extent, published clinical practice guidelines for the treatment of chronic tinnitus vary in their recommendations.

DESIGN

Systematic review of guidelines.

DATA SOURCES

PubMed, EMBASE and GIN electronic databases were searched in March 2022 and the search was updated in June 2023.

ELIGIBILITY CRITERIA

We included clinical practice guidelines that gave recommendations on the treatment of tinnitus. No language restrictions were applied.

DATA EXTRACTION AND SYNTHESIS

Two independent reviewers extracted the data and used the AGREE checklist to report on reporting.

RESULTS

A total of 10 guidelines were identified and included, published between 2011 and 2021. Recommendations for 13 types of tinnitus treatments were compared. Large differences in guideline development and methodology were found. Seven of the 10 guidelines included a systematic search of the literature to identify the available evidence. Six of the 10 guidelines used a framework for the development of the guideline. Reporting was poor in multiple guidelines. Counselling and cognitive behavioural therapy were the only treatments that were recommended for treating tinnitus associated distress by all guidelines that reported on these topics. Tinnitus retraining therapy, sound therapy, hearing aids and cochlear implantation were not unanimously recommended either due to the lack of evidence, a high risk of bias or judgement of no beneficial effect of the specific treatment.

CONCLUSIONS

There were notable differences with respect to whether guidelines considered the available evidence sufficient enough to make a recommendation. Notably, we identified substantial differences in the rigour of guideline design and development. Reporting was poor in many guidelines. Future guidelines could benefit from the use of reporting tools to improve reporting and transparency and the inclusion of guideline experts and patients to improve the quality of clinical practice guidelines on tinnitus.

Management of Migraine-Associated Vestibulocochlear Disorders

Migraine is a chronic neurological disorder that frequently coexists with different vestibular and cochlear symptoms (sudden hearing loss, tinnitus, otalgia, aural fullness, hyperacusis, dizziness, imbalance, and vertigo) and disorders (recurrent benign positional vertigo, persistent postural perceptual dizziness, mal de debarquement, and Menière's disease). Despite evidence of an epidemiological association and similar pathophysiology between migraine and these vestibulocochlear disorders, patients suffering from migraine-related symptoms are usually underdiagnosed and undertreated. Current migraine treatment options have shown success in treating vestibulocochlear symptoms. Lifestyle and dietary modifications (reducing stress, restful sleep, avoiding migraine dietary triggers, and avoiding starvation and dehydration) and supplements (vitamin B2 and magnesium) offer effective first-line treatments. Treatment with migraine prophylactic medications such as tricyclic antidepressants (e.g., nortriptyline), anticonvulsants (e.g., topiramate), and calcium channel blockers (e.g., verapamil) is implemented when lifestyle and dietary modifications are not sufficient in improving a patient's symptoms. We have included an algorithm that outlines a suggested approach for addressing these symptoms, taking into account our clinical observations. Greater recognition and understanding of migraine and its related vestibular and cochlear symptoms are needed to ensure the appropriate diagnosis and treatment of affected patients.